Jazz Pharmaceuticals plc Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt
Jazz Pharmaceuticals plc (JAZZ) reported Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt of $176.26 million for the 3-month period ending 2020-06-30, per its 10-Q filed 2020-11-02.
Discontinued › Shareholders' Equity
us-gaap:AdjustmentsToAdditionalPaidInCapitalEquityComponentOfConvertibleDebt · last filed 2020-11-02
- Jazz Pharmaceuticals plc adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2020-06-30 was $176.26M.
- Jazz Pharmaceuticals plc adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2017-12-31 was $0.00.
- Jazz Pharmaceuticals plc adjustments to additional paid in capital, equity component of convertible debt for the quarter ending 2014-12-31 was $1.00K.
- Jazz Pharmaceuticals plc adjustments to additional paid in capital, equity component of convertible debt for fiscal 2017 was $149.77M.
- Jazz Pharmaceuticals plc adjustments to additional paid in capital, equity component of convertible debt for fiscal 2014 was $126.86M.
| Period end | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 3 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 9 month | Adjustments to Additional Paid in Capital, Equity Component of Convertible Debt 12 month |
|---|---|---|---|
| 2020-06-30 | $176.26M 10-Q · filed 2020-11-02 | ||
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $149.77M 10-K · filed 2020-02-25 | |
| 2017-09-30 | $149.77M 10-Q · filed 2018-11-06 | ||
| 2014-12-31 | $1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | $126.86M 10-K · filed 2017-02-28 | |
| 2014-09-30 | $126.86M 10-Q · filed 2015-11-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| Elanco Animal Health Inc (ELAN) | United States | $11.177B | -61.80 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |